BOVISEAL DRY COW INTRAMAMMARY INFUSION
Country: Írland
Tungumál: enska
Heimild: HPRA (Health Products Regulatory Authority)
Vara einkenni
(SPC)
05-08-2015
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
BISMUTH SUBNITRATE
Fáanlegur frá:
Cross Vetpharm Group Limited
ATC númer:
QJ51X
INN (Alþjóðlegt nafn):
BISMUTH SUBNITRATE
Skammtar:
2.6 g/syringe
Lyfjaform:
Intramammary Infusion
Gerð lyfseðils:
LM-Licensed Merchant
Meðferðarhópur:
Bovine
Lækningarsvæði:
OTHER ANTIBACTERIALS FOR INTRAMAMMARY USE
Ábendingar:
Miscellaneous
Leyfisstaða:
Authorised
Leyfisdagur:
2003-06-30
Vara einkenni
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Boviseal Dry Cow Intramammary Infusion
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substance
Bismuth subnitrate
2.6g per 4g syringe
For a full list of excipients, see Section 6.1
3 PHARMACEUTICAL FORM
Intramammary infusion, dry cow.
Grey to white coloured cream.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dairy cows at the end of lactation.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Boviseal is indicated for the prevention of new intramammary infections throughout the dry period. This results in a
reduction in the incidence of subclinical mastitis in cows at calving, and of clinical mastitis in the dry period and the
subsequent lactation (for at least 60 days after calving).
It is recommended that Boviseal be used as part of a herd approach to dry cow management and mastitis control. Cows
considered likely to be free of subclinical mastitis should be given Boviseal at drying off according to the criteria below.
Other animals should be managed in accordance with an approved mastitis control plan or specific veterinary advice.
For practical purposes, selection criteria may be based on the mastitis and cell count history of individual cows, or
recognised tests for the detection of subclinical mastitis or bacteriological sampling. It is particularly important that, prior to
treatment, an individual cell count be obtained from any cow with a history of clinical mastitis during the previous
lactation. As a guide, cows with an average cell count less than 200,000 cells/ml before drying off may be given Boviseal.
A minor increase (cell count up to 250,000 cells/ml) during the last 4 weeks before drying off is normal and may be
ignored. In case of doubt, veterinary advice shoul
Lestu allt skjalið
